Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9515116 | 0.85 | MEN1 (0.50) | MEN1KMT2AMTORALDH1A1POLB | |
| SCHEMBL19481465 | 0.84 | MTOR (0.59) | MEN1KMT2AMTORALDH1A1POLB | |
| SCHEMBL14768578 | 0.84 | MTOR (0.59) | MEN1KMT2AMTORALDH1A1POLB | |
| SCHEMBL12783364 | 0.84 | MTOR (0.59) | MEN1KMT2AMTORALDH1A1POLB | |
| SCHEMBL14368075 | 0.79 | GAA (0.64) | ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL14338232 | 0.79 | GAA (0.64) | ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL14338233 | 0.79 | GAA (0.64) | ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL14197120 | 0.79 | GAA (0.64) | ALDH1A1GAAKDM4ELMNA | |
| SCHEMBL16168058 | 0.79 | MEN1 (0.56) | MEN1KMT2AMTORALDH1A1POLB | |
| SCHEMBL24316284 | 0.78 | MEN1 (0.46) | MEN1KMT2AMTORGAAAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | RAQUALIA PHARMA INC. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-8859812-B2 | Compound reagents and method for synthesizing enantiomerically enriched amino acids | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | MEN1 3786/4885KMT2A 4196/4885MTOR 2196/4885 |
| US-20230255965-A1 | TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES | TRPV4, TRPV5, TRPV2 | MEN1 3443/4885KMT2A 2654/4885MTOR 949/4885 |
| US-20130066109-A1 | COMPOUNDS AND RELATED METHODS OF USE | BCAT2, BCAT1, AADAT | MEN1 404/4885KMT2A 3292/4885MTOR 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.